Adherence to the guidelines of the CCCE in the treatment of node-positive breast cancer patients

European Journal of Cancer

Volumn 40, Issue 2, 2004, Pages 198-204

  Ottevanger, P B ^a   De Mulder, P H M ^a   Grol, R P T M ^a   Van Lier, H ^a   Beex, L V A M ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Breast cancer; Guideline implementation; Indicators; Quality improvement

Indexed keywords

ANTINEOPLASTIC AGENT; CMF REGIMEN; CYCLOPHOSPHAMIDE; ESTROGEN RECEPTOR; FLUOROURACIL; METHOTREXATE; PROGESTERONE;

ADULT; AGED; ARTICLE; AXILLARY LYMPH NODE; BREAST CARCINOMA; BREAST SURGERY; BREAST TUMOR; CANCER CENTER; CANCER CHEMOTHERAPY; CANCER GRADING; COMPARATIVE STUDY; CONTROLLED STUDY; FEEDBACK SYSTEM; FEMALE; HEALTH CARE; HUMAN; LYMPH NODE; LYMPH NODE METASTASIS; MEDICAL ASSESSMENT; MEDICAL AUDIT; METHODOLOGY; PATHOLOGY; PRACTICE GUIDELINE; PREMENOPAUSE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SEGMENTAL MASTECTOMY; TUMOR DIFFERENTIATION;

EID: 0347285237     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0959-8049(03)00660-9     Document Type: Article

References (15)

1. Grimshaw J.M., Russell I.T. Effect of clinical guidelines on medical practice. a systematic review of rigorous evaluations Lancet. 342:1993;1317-1322.
2. Fletcher S.W., Fletcher R.H. Development of clinical guidelines. Lancet. 352:1998;1876.
3. Morris M., Levenback C., Burke T.W., Dejesus Y., Lucas K.R., Gershenson D.M. An outcomes management program in gynecologic oncology. Obstet. Gynecol. 89:1997;485-492.
4. Ottevanger P.B., Verhagen C.A., Beex L.V. Quality of adjuvant chemotherapy in primary breast cancer in a non-trial setting. A comprehensive cancer centre study. The Breast Cancer Group of the Dutch Comprehensive Cancer Centre East (IKO). Eur. J. Cancer. 35:1999;386-391.
5. Ottevanger P.B., De Mulder P.H., Grol R.P., Van Lier H., Beex L.V. Effects of quality of treatment on prognosis in primary breast cancer patients treated in daily practice. Anticancer Res. 22:2002;459-465.
6. Bonadonna G., Valagussa P. Dose-response effect of adjuvant chemotherapy in breast cancer. N. Engl. J. Med. 304:1981;10-15.
7. Bonadonna G., Valagussa P., Moliterni A., Zambetti M., Brambilla C. Adjuvant cyclophosphamide, methotrexate, and fluorouracil in node- positive breast cancer. the results of 20 years of follow-up N. Engl. J. Med. 332:1995;901-906.
8. Wood W.C., Budman D.R., Korzun A.H.et al. Dose and dose intensity of adjuvant chemotherapy for stage II, node-positive breast carcinoma. N. Engl. J. Med. 330:1994;1253-1259.
9. Recht A., Come S.E., Henderson I.C.et al. The sequencing of chemotherapy and radiation therapy after conservative surgery for early-stage breast cancer. N. Engl. J. Med. 334:1996;1356-1361.
10. Overgaard M., Hansen P.S., Overgaard J.et al. Postoperative radiotherapy in high-risk premenopausal women with breast cancer who receive adjuvant chemotherapy. Danish Breast Cancer Cooperative Group 82b Trial. N. Engl. J. Med. 337:1997;949-955.
11. Riley G.F., Potosky A.L., Klabunde C.N., Warren J.L., Ballard-Barbash R. Stage at diagnosis and treatment patterns among older women with breast cancer. an HMO and fee-for-service comparison JAMA. 281:1999;720-726.
12. Sant M. Differences in stage and therapy for breast cancer across Europe. Int. J. Cancer. 93:2001;894-901.
13. Ozer H., Armitage J.O., Bennett C.L.et al. 2000 Update of Recommendations for the use of hematopoietic colony-stimulating factors. evidence-based, clinical practice guidelines J. Clin. Oncol. 18:2000;3558.
14. Grilli R., Lomas J. Evaluating the message. the relationship between compliance rate and the subject of a practice guideline Med. Care. 32:1994;202-213.
15. Grol R., Dalhuijsen J., Thomas S., Veld C., Rutten G., Mokkink H. Attributes of clinical guidelines that influence use of guidelines in general practice. observational study Br Med J. 317:1998;858-861.